Sacituzumab Govitecan in Triple-Negative Breast Cancer

No. It is an antibody-drug conjugate. An antibody that recognises the Trop-2 protein carries a chemotherapy payload called SN-38 and releases it mainly inside cells carrying that protein. It is chemotherapy with a delivery system, not a treatment that works through the immune system. Pembrolizumab is the immunotherapy in triple-negative breast cancer.

This matters more here than on most molecule pages, because the two audiences are the same people. A family reading about triple-negative breast cancer is reading about immunotherapy within a day or two, and the search results mix antibody-drug conjugates, checkpoint inhibitors and chemotherapy together without ever saying which is which.

The distinction is not academic. A checkpoint inhibitor is chosen on a PD-L1 test. An antibody-drug conjugate is chosen on the line of treatment and what has already been used. They have different side effects, different monitoring, and — in India — completely different availability. Since June 2026 they are also approved for use together in one first-line setting abroad, which makes the labels harder rather than easier to keep apart.

Adults with advanced breast cancer only, in defined settings. Every approved indication is unresectable locally advanced or metastatic disease. There is no approved indication in early-stage breast cancer treated with curative intent. Which setting applies depends on the line of treatment, prior therapy and, for one indication, a PD-L1 combined positive score of 10 or more.

Triple-negative breast cancer is reported to account for approximately 15 per cent of breast cancers. It is the subtype with the fewest targeted options, which is exactly why families researching it move quickly from one unfamiliar molecule name to the next. The approvals below are all foreign; none of them is an Indian approval.

What the trials behind the June 2026 approvals reported. In ASCENT-03, in 558 previously untreated patients who were not candidates for PD-1 or PD-L1 inhibitor therapy, the confirmed objective response rate was 50 per cent with sacituzumab govitecan and 47 per cent with the chemotherapy comparator. In ASCENT-04/KEYNOTE-D19, in 443 patients with PD-L1 combined positive score of 10 or more, it was 61 per cent with sacituzumab govitecan plus pembrolizumab and 55 per cent with chemotherapy plus pembrolizumab. Overall survival data were immature at approval in both trials. These are response rates in selected trial populations, not a prediction for any individual, and they say nothing about how long a response lasts.

Not on the ordinary Indian market, on the information available in August 2026. No record of a CDSCO marketing approval could be found, and published sources describe the molecule as not commercially marketed here. Indian law separately allows an unregistered medicine to be imported in a named individual patient’s name, on prescription. Regulatory status changes, so treat this as unconfirmed rather than settled.

That is an uncomfortable answer, and it is the honest one. Being unable to find an approval is not the same as proving there is none: approvals are not always published promptly, and a marketing authorisation can be granted without a launch following it. What can be said is that as of August 2026 there is no Indian brand, no listed MRP, and no notified ceiling price for this molecule.

What a named-patient import actually involves. The medicine is imported in one patient’s name against that patient’s prescription and reports, with an import permit where one is required. It is not a purchase off a shelf. It carries a longer lead time, a cold chain that has to hold at 2–8°C from the source country to the day-care unit, customs handling, and no local recourse if a batch is mishandled in transit. None of that is a reason to rule it out; all of it is a reason to have the treating team drive the process rather than a family working alone.

Two related risks are worth reading before anyone starts down this road. Counterfeit Immunotherapy Drugs in India covers what has actually been reported entering the Indian market, and Immunotherapy Cold Chain and Storage explains why a vial that has been out of temperature range cannot be identified by looking at it. An unregistered medicine bought outside a hospital supply chain sits squarely in the middle of both problems.

Most people with breast cancer are not candidates, and the fact that a medicine is newer does not place anyone in line for it. Every approved indication is advanced disease. Eligibility is decided by the pathology report, the line of treatment and what has already been used — not by how much a family is prepared to spend importing it.

• Not for early-stage breast cancer. There is no approved indication in disease being treated with curative intent. Surgery, chemotherapy, radiotherapy and endocrine treatment are the plan there, and substituting this molecule for any of them is not an option a treating team would offer.
• Not for HER2-positive breast cancer. That is a separate pathway with its own HER2-directed medicines. Trastuzumab and Trastuzumab Deruxtecan in Breast Cancer covers the antibody-drug conjugate used there, which is a different molecule with different approvals.
• Not a replacement for a checkpoint inhibitor where one is indicated. If the tumour is PD-L1 positive and a checkpoint inhibitor is the recommended first-line option, this is not an alternative to it — in the June 2026 first-line approval the two are used together, not instead of each other.
• Not straightforward in reduced UGT1A1 enzyme activity. The US prescribing information lists this as a warning, because SN-38 is cleared through that enzyme and reduced activity raises the risk of severe neutropenia. It changes how the treating team weighs the decision.
• Not in pregnancy. The label carries an embryo-fetal toxicity warning. Effective contraception is advised during treatment and for a period afterwards, and breastfeeding is not recommended; the intervals are set by the treating team.
• Not sensible without reliable, fast access to a treating hospital. The boxed warnings are severe neutropenia and severe diarrhoea. Both can escalate within hours. Someone who cannot reach the hospital treating them quickly when a fever starts is in a genuinely difficult position on this medicine, and that is part of the eligibility conversation, not an afterthought.

None of the above is a judgement about whether the medicine works. It is a description of who its approvals cover and what safe use requires. For anyone outside those settings, the useful next conversation is about the options that do apply, which the treating oncologist can set out against the actual pathology report.

By intravenous infusion at 10 mg/kg, on day 1 and day 8 of each 21-day cycle. Treatment continues until the disease progresses or the side effects become unacceptable. Doses above 10 mg/kg are not recommended. It is given as an infusion only, never as a push or a bolus. The first infusion runs over about three hours.

1. Blood counts before dosing. The neutrophil count is checked before each dose, and a dose is delayed or reduced if the count is too low. This is routine, not a sign that something has gone wrong.
2. Pre-medication. Anti-sickness medicines are usually given beforehand, and pre-medication for infusion reactions may be used.
3. The first infusion, over about three hours. The patient is observed during it and for a period after it, because hypersensitivity and infusion reactions are recognised effects.
4. Later infusions, over one to two hours. Only if the first was tolerated. Observation continues.
5. Two doses per cycle, then a week off. Days 1 and 8, then day 15 free, and the next cycle begins on day 22.
6. Reviewed, not counted down. Because the schedule runs until progression or unacceptable toxicity, the number of cycles is not fixed at the start. Response is assessed on scans at intervals the treating team sets.

What that means in vials. The medicine is supplied as a lyophilised powder in single-dose vials, reconstituted by a pharmacist or nurse. At 10 mg/kg, an adult of about 60 kg needs 600 mg per dose — roughly four 180 mg single-dose vials each time, so in the region of eight vials per 21-day cycle. That is arithmetic on the labelled dose, not a quotation, and body weight moves it substantially in either direction. Vials are stored refrigerated at 2–8°C, protected from light, and never frozen.

There is no Indian price, because there is no Indian market for it. No MRP, no NPPA ceiling, no hospital rate card. The clearest published anchor is Canadian: a sponsor-submitted price of 1,478 Canadian dollars per 180 mg vial, recorded in the CADTH reimbursement review of February 2022, with an estimated cost of about 12,478 Canadian dollars per 21-day cycle.

Why converting that into rupees would mislead. A Canadian payer price is a negotiated list price in a market where the medicine is registered and reimbursed. A named-patient import into India is a different transaction: the cost depends on the source country’s ex-market price, the number of vials the patient’s weight requires, validated cold-chain logistics, insurance, customs duty and permit handling. Two families importing the same medicine in the same month can land at genuinely different figures. Anyone quoting a single confident rupee number for this molecule should be asked which of those components it includes.

The comparison families usually want next. Pembrolizumab is marketed in India, has an Indian price, and is the medicine most often meant when a TNBC discussion turns to immunotherapy — Pembrolizumab (Keytruda) Cost in India sets out that picture with the same sourcing discipline. It is a different medicine for a different question, but for most families in Telangana and Andhra Pradesh it is the more immediately relevant number.

One caution on the open-ended schedule: because treatment runs until progression or unacceptable toxicity rather than for a fixed count, no one can state a total course cost in advance. A total that is quoted confidently is an assumption about duration wearing the clothes of a fact.

Two carry a boxed warning in the US label: severe neutropenia and severe diarrhoea. A fever while the white cell count is low is a medical emergency, not something to watch overnight. Diarrhoea that is not settling causes dehydration quickly. Anyone with either should go to the hospital treating them the same day and say which medicine they are on.

One point that should not be softened. Febrile neutropenia is an emergency. A temperature over 38°C on this medicine means going to the hospital treating the patient straight away, at any hour, without waiting to see whether it settles — and saying at the desk which medicine and which cycle day. That single sentence matters more than anything else on this page.

The side-effect pattern here is a chemotherapy pattern, not the immune pattern that checkpoint inhibitors produce. Anyone comparing the two will find the difference stark, and Pembrolizumab Side Effects: What to Watch For sets out the immune-related side of it — colitis, thyroid changes, pneumonitis — which looks nothing like this table.

• Pembrolizumab (Keytruda): What It Is and How It Is Used — the checkpoint inhibitor most families mean when they say immunotherapy in triple-negative breast cancer.
• Pembrolizumab (Keytruda) Cost in India — the medicine that does have an Indian price, and what moves it.
• Pembrolizumab Side Effects: What to Watch For — the immune-related pattern, which is not the pattern on this page.
• Trastuzumab and Trastuzumab Deruxtecan in Breast Cancer — the antibody-drug conjugate used in HER2-positive disease, and its Indian approval trail.
• Immunotherapy Medicines Explained — the index of checkpoint inhibitors, antibodies and molecule-by-molecule cost pages.
• Immunotherapy at CION — what this class of treatment does, who it suits, and who it does not.

Editorial information about a named medicine — not an offer, a price list, or a recommendation to use it, and no comparative quality claim between manufacturers or suppliers. No importer, supplier or pharmacy is named or endorsed anywhere on this page, and nothing here is a supply, import or pricing service. All regulatory, dosing and cost statements are indicative and dated to August 2026, drawn from published regulatory approval announcements, approved product information and a published Canadian payer submission. Indian regulatory status could not be confirmed either way at the time of writing and is stated as unconfirmed. Whether sacituzumab govitecan has any role in a particular cancer is a decision for the treating oncologist, on the basis of the pathology report and the full clinical picture.